Clinical trials: Normal Population
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
This randomized, parallel-group study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) versus adalimumab, both in combination with methotrexate (MTX) in patients with moderate to severe active rheumatoid…
- Trial name
- NCT01283971
- Testing
- tocilizumab [RoActemra/Actemra], adalimumab, methotrexate
- Where
- 170 sites in United States, Denmark and 10 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Psoriasis
Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)
Protocol Title: A Phase 1, first-in-human, randomized, double-blind, single-dose, parallel-group, 3-arm study comparing the pharmacokinetic, safety, tolerability, and immunogenicity profiles of AVT04, EU approved Stelara®, and…
- Trial name
- NCT04744363
- Testing
- Stelara PFS
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Alvotech Swiss AG
Atopic Dermatitis
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.
- Trial name
- NCT03100344
- Testing
- Nemolizumab
- Where
- 67 sites in United States, Australia and 4 more
- Volunteers
- 226 people
- Sponsor
- Galderma R&D
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on…
- Trial name
- ANIMA - Italy (NCT07543419)
- Where
- 16 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis will be randomized to receive either…
- Trial name
- NCT00770965
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Safety Study of Abatacept to Treat Rheumatoid Arthritis
The purpose of this study is to compare the incidence rates of infection, malignancy and death among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic…
- Trial name
- NCT01247766
- Volunteers
- 6,367 people
- Sponsor
- Bristol-Myers Squibb
Hypochondroplasia
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children
This study is conducted to describe the efficacy and safety of recombinant human growth hormone (r-hGH) treatment Saizen® on children with hypochondroplasia.
- Trial name
- NCT01111019
- Testing
- Recombinant human growth hormone (r-hGH)
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Atopic Dermatitis (AD)
A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis
To investigate the superiority of 0.3% OPA-15406 foam to the vehicle in children with atopic dermatitis (AD)
- Trial name
- NCT07184645
- Testing
- OPA-15406, Vehicle
- Where
- Japan
- Volunteers
- 198 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Actinic Keratosis (AK)
A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period
Once or twice daily 12 week treatment in patients with Actinic Keratosis randomized to treatment in one of four arms.
- Trial name
- NCT03116698
- Testing
- Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily
- Where
- 20 sites in United States
- Volunteers
- 240 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Atopic Dermatitis
A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.
- Trial name
- NCT06438263
- Testing
- Rocatinlimab
- Where
- 3 sites in United States
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Amgen
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia
- Trial name
- NCT05677438
- Testing
- CKD-498 dose#1, CKD-498 dose#2, CKD-498 dose#3
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Acne Vulgaris
A Study on Safety and Preliminary Efficacy of ALA in Acne Vulgaris
The purpose of this study is to explore the safety, tolerability, and preliminary efficacy of ALA used with photodynamic therapy for the treatment of moderate to severe acne vulgaris.
- Trial name
- NCT04018885
- Testing
- ALA 2.5%, ALA 5%, ALA 10%
- Where
- 4 sites in China
- Volunteers
- 72 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Acne Vulgaris
To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1%/ Benzoyl peroxide 5% topical gel (Glenmark Generics, Ltd), and the…
- Trial name
- NCT02465632
- Testing
- Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel, BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%
- Where
- 15 sites in United States, Belize
- Volunteers
- 1,100 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Vitiligo
Efficacy and Safety of ACH24 in the Treatment of Vitiligo
This is a multicenter clinical trial, phase III, randomized, placebo-controlled, parallel group, enroll 94 patients, to assess the efficacy of ACH24 in the repigmentation of achromatic areas in patients with vitiligo.
- Trial name
- NCT01419964
- Testing
- Group 01, Group 02
- Where
- Brazil
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Actinic Keratosis
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than…
- Trial name
- NCT02952898
- Testing
- GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel
- Where
- 16 sites in United States
- Volunteers
- 665 people
- Sponsor
- Balmoral Medical company
Onychomycosis
Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus.
- Trial name
- NCT00443898
- Testing
- terbinafine
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 518 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in subjects with resected advanced melanoma requiring…
- Trial name
- NCT06153238
- Testing
- GME751, Keytruda - EU, Keytruda - US
- Where
- 61 sites in United States, Bosnia and Herzegovina and 16 more
- Volunteers
- 322 people
- Sponsor
- Sandoz
Arthritis, Rheumatoid
SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate
The primary objective of this study is to determine the efficacy of oral SCIO-469 in patients with rheumatoid arthritis who are not receiving liver damaging (hepatotoxic) disease-modifying anti-rheumatic drugs (DMARDs).
- Trial name
- NCT00089921
- Testing
- SCIO-469
- Volunteers
- 302 people
- Sponsor
- Scios, Inc.
Acne Vulgaris
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in the treatment of Acne Vulgaris.
- Trial name
- NCT00599521
- Testing
- Adapalene lotion 0.1%, Adapalene Lotion Vehicle
- Where
- 34 sites in United States, Canada
- Volunteers
- 1,067 people
- Sponsor
- Galderma R&D
Acne Vulgaris
P3 Study in Acne Comparing Once Daily SB204 and Vehicle
This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.
- Trial name
- NCT02672332
- Testing
- SB204 4%, Vehicle Gel
- Where
- 55 sites in United States
- Volunteers
- 1,307 people
- Sponsor
- Novan, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.